Baxter International Inc. (BAX) Stock AnalysisBAXBaxter International Inc.

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Baxter International Inc is a good buy right now due to its current price of $25.28, which is below the average analyst price target of $27.67, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +29.64% and a recent 5-day change of +3.82%, suggesting positive momentum. However, the main risk is the negative net income reported in Q4 2024 at -$512 million, which reflects ongoing profitability challenges that investors should monitor closely.